Target intelligence / Profile preview

Ectopic P granules protein 5 homolog (EPG5)

Target
EPG5
Molecular classification
Other (Autophagy tethering factor; large coiled-coil protein), Protein involved in membrane trafficking, Not classified as receptor, enzyme, transporter, ion channel, or transcription factor
01

Overview

Ectopic P granules protein 5 homolog (EPG5) is a large metazoan-specific coiled-coil protein (~290 kDa) that functions as a tethering factor in macroautophagy, specifically mediating the fusion between autophagosomes and lysosomes to ensure specificity and prevent mistargeting. EPG5 interacts preferentially with the GABARAP subfamily of ATG8 proteins through unique tandem LC3-interacting regions (LIR motifs) to facilitate and regulate autophagosome–lysosome fusion. Deficiency in EPG5 leads to mistargeting, impaired autophagic flux, and accumulation of dysfunctional vesicles, contributing to the pathogenesis of Vici syndrome—a severe multisystem disorder affecting brain, immune system, heart, skin, and eyes. EPG5 also plays a role in cellular immune responses to intracellular pathogens. There are currently no drugs targeting EPG5 directly, and mutations are primarily relevant as diagnostic biomarkers for Vici syndrome.

Other names
EPG5Ectopic P-granules 5 autophagy tethering factorKIAA1632hEPG5HEEW1VICISEctopic P-granules autophagy protein 5 homolog
02

Mechanism of action

Not applicable; no drugs specifically modulate EPG5 function as a primary target

03

Biological functions

Autophagosome-lysosome fusion (autophagy)Cargo clearance via autophagyInnate and adaptive immune responseRecognition and response to intracellular infection (bacteria/viruses)Cellular homeostasis during starvation conditions
04

Disease associations

Neurodevelopmental disease (Vici syndrome)ImmunodeficiencyCardiomyopathy (Vici syndrome context)Oculocutaneous hypopigmentation (Vici syndrome context)Multisystem disorder/other organ involvement (Vici syndrome)
05

Safety considerations

EPG5 deficiency causes impaired autophagy and broad multi-organ dysfunction, but protein targeting for therapy is not established; safety considerations would be hypothetical at present and relate to inhibition of essential autophagic function
06

Interacting drugs

No drugs known to directly target EPG5 for clinical use. Current literature does not report any approved or investigational chemical drugs that modulate EPG5 directly
07

Biomarkers

Mutations in EPG5 used as biomarkers for diagnosis of Vici syndromeNo known biomarkers for efficacy monitoring of drugs targeting EPG5

Beyond the preview

Go deeper on Ectopic P granules protein 5 homolog (EPG5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ectopic P granules protein 5 homolog (EPG5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call